Xenon Pharmaceuticals Inc (XENE) Financials

Key financial figures for Xenon Pharmaceuticals Inc (Q2 2026).

Xenon Pharmaceuticals Inc. reported revenue of $0.00 for Q2 FY2026. The company posted a net loss of $110.7 million, or -$1.11 per share. Free cash flow for the period was -$95.7 million. The figures above are as filed, and the full income statement, balance sheet and cash flow history for Xenon Pharmaceuticals Inc. are on the SentiSense financials page.

Revenue
$0
Net Income
-$111M
EPS
$-1.11
Total Assets
$1.3B
Operating Cash Flow
-$95M

Recent quarters

PeriodRevenueNet IncomeEPSOperating MarginFree Cash Flow
Q2 FY2026$0-$111M-$1.11-$96M
Q1 FY2026$0-$102M-$1.17-$89M
Q4 FY2025$0-$105M-$1.31-$82M
Q3 FY2025$0-$91M-$1.15-$72M
Q2 FY2025$0-$85M-$1.07-$64M

Recent fiscal years

PeriodRevenueNet IncomeEPSOperating MarginFree Cash Flow
FY2025$8M-$346M-$4.36-4974.27%-$280M
FY2024$0-$234M-$3.01-$184M
FY2023$0-$182M-$2.73-$151M

Frequently asked questions

What was Xenon Pharmaceuticals Inc.'s revenue last quarter?

Xenon Pharmaceuticals Inc. reported revenue of $0.00 for Q2 FY2026.

Is Xenon Pharmaceuticals Inc. profitable?

Not in its most recent reported period. Xenon Pharmaceuticals Inc. reported a net loss of $110.7 million for Q2 FY2026.

How much free cash flow did Xenon Pharmaceuticals Inc. generate?

Xenon Pharmaceuticals Inc. generated free cash flow of -$95.7 million in Q2 FY2026, after capital expenditure.

Full income statement, balance sheet and cash flow for Xenon Pharmaceuticals Inc on SentiSense, with up to forty quarters and twenty fiscal years of history.